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a b s t r a c t
Next-generation sequencing (NGS) analysis of thyroid samples aids in risk stratiﬁcation of cytologically
indeterminate nodules and contributes to our understanding of molecular mechanisms in thyroid neoplasia. Several genes, including BRAF, RAS, and EIF1AX, are known to play a role in thyroid tumorigenesis.
Here we report a case of papillary thyroid carcinoma (PTC) in which a single lesion harbored a novel
YWHAG-BRAF fusion and EIF1AX mutation and displayed mixed morphological ﬁndings. The patient is a
74-year-old female with multiple incidentally discovered thyroid nodules, two of which were sampled by
ultrasound-guided ﬁne needle aspiration (FNA). Cytologic diagnosis for both nodules was suspicious for
follicular neoplasm (Bethesda Category IV). NGS testing of one nodule detected a novel in-frame YWHAGBRAF fusion and a concurrent EIF1AX A113 splice mutation. The subsequent surgical resection specimen
showed that this nodule exhibited two distinct morphologic patterns, conventional (classical) type and
follicular variant (FV) of PTC, which were sharply demarcated and were found to harbor unique genetic
alterations. Of note, this is the ﬁrst report of BRAF activation through novel rearrangement with a gene
encoding a 14–3–3 protein as a pathogenic factor, which underlines its signiﬁcance both as a prognostic
measurement and as a therapeutic target.
© 2022 The Authors. Published by Elsevier Inc.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)

Introduction
Up to 30% of biopsied thyroid nodules receive an indeterminate
cytologic diagnosis of either “atypia of undetermined signiﬁcance
(AUS)/follicular lesion of undetermined signiﬁcance (FLUS)” or “follicular neoplasm (FN)/suspicious for follicular neoplasm (SFN)”,
Bethesda categories III and IV, respectively [1]. The reported risks
of malignancy for these categories are highly variable, complicating
the clinical management of these indeterminate nodules. Molecular analysis, notably via next-generation sequencing (NGS), has
emerged as an important supplemental tool for evaluating thyroid
nodules [2]. NGS testing of thyroid ﬁne needle aspiration (FNA)
specimens can help with the risk stratiﬁcation of cytologically indeterminate thyroid nodules and provide insight into the mechanism of thyroid tumorigenesis.
The most commonly known mutated genes associated with thyroid malignancies are BRAF and RAS. The majority of BRAF mutations are found in classical papillary thyroid carcinoma (PTC),

while RAS mutations are seen in follicular variant of papillary thyroid carcinoma (FVPTC) and other malignant and benign follicularpatterned thyroid lesions [3]. More recently, mutations in other
genes such as EIF1AX (Eukaryotic translation initiation factor 1A,
X-chromosomal), as well as gene fusions, have been detected in
various types of thyroid cancer as well as in some benign thyroid
nodules [4,5].
We report a case of an adult patient with multiple thyroid nodules harboring several distinct genetic abnormalities detected by
NGS, which greatly inﬂuenced the clinical decision making. One
of the molecular alterations is a BRAF fusion with a novel partner gene, YWHAG (also known as 14–3–3 GAMMA or tyrosine
3-monooxygenase/tryptophan 5-monooxygenase activation protein
gamma), which has not been previously reported. In addition, a
coexisting EIF1AX mutation was identiﬁed in that same nodule,
which upon surgical resection exhibited two distinct histological
patterns of PTC.
Case presentation
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The patient is a 74-year-old female who presented to the Otolaryngology Clinic for work-up of incidentally discovered thyroid
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Fig. 1. Clinical timeline.

nodules. A brief clinical timeline is shown in Fig. 1. The patient denied any signiﬁcant symptoms like dysphagia, weight loss, hoarseness or night sweats. She reported a family history of goiter in her
aunt and grandmother, but no family history of thyroid cancer. Her
physical exam was notable for a normal-sized thyroid with mild
nodularity, which moved easily beneath the strap muscles, no palpable cervical lymphadenopathy and normal vocal fold mobility on
ﬁberoptic nasopharyngolaryngoscopy. Ultrasonography of the neck
revealed two nodules in the left lobe, one nodule in the left isthmus, two nodules in the right lobe, and no pathologic appearing
lymphadenopathy.
Initially, a 1.2 cm left lobe nodule and the 1.6 cm left isthmic
nodule underwent FNA and both received a cytologic diagnosis of
“SFN (Bethesda Category IV)”. The FNA specimens were cellular
with the follicular cells arranged predominantly in crowded, microfollicular clusters. In addition to this architectural atypia, both
nodules also displayed atypical nuclear features such as enlargement and contour irregularities including grooves; therefore, the
cytologic differential diagnosis included non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) and
FVPTC. Molecular analysis was subsequently performed.
Total nucleic acids were extracted from selected areas of
formalin-ﬁxed, paraﬃn-embedded (FFPE) tumor tissue with QIAamp DNA FFPE Kit (Qiagen) and from FNA with QIAamp DNA Micro Kit (Qiagen). Archer VariantPlexTM Comprehensive Thyroid and
Lung Panel (ArcherDX/Invitae) was used for the detection of gene
mutations in genomic DNA. Archer FusionPlexTM Comprehensive
Thyroid and Lung Panel (ArcherDX/Invitae) was used for the detection of fusion genes in RNA with the Archer Anchored Multiplex
PCR chemistry. This library chemistry allows the detection of both
known and unknown fusion partners of queried genes contained
in the panel. NGS libraries were sequenced on NextSeq550 Dx (Illumina). Sequencing data were analyzed using the Archer Analysis

6.0 software with bioinformatics pipelines for the detection of gene
mutations (SNP/Indel) and gene fusions.
Molecular testing of the FNA specimen showed a novel
YWHAG/BRAF fusion (Fig. 2), along with the EIF1AX A113 splice mutation in the left lobe nodule and the KRAS Q61R mutation in the
left isthmus nodule (Table 1).
After cytology and molecular results for the two suspicious left
thyroid nodules were reviewed, the recommendation for left thyroid lobectomy and isthmusectomy was made based on the overall risk of malignancy, the size of these nodules, and the absence
of more concerning ultrasonographic or physical exam ﬁndings.
Intraoperatively, she was noted to have several smooth and soft
left lobe nodules without gross extrathyroidal extension or central
neck lymphadenopathy.
Surgical pathology examination of the left thyroid lobectomy
and isthmusectomy showed two organ-conﬁned foci of PTC. The
isthmic nodule showed FVPTC (Table 1). Interestingly, the left lobe
nodule exhibited two distinct morphologic patterns, conventional
(classical) type and follicular variant (FV) of PTC, with a clear demarcation between them (Fig. 3). Of note, multiple foci of papillary microcarcinoma, a microscopic hyalinizing trabecular tumor,
chronic lymphocytic thyroiditis, and nodular thyroid hyperplasia
were also identiﬁed in the specimen.
To understand the pathogenesis and the correlation between
morphology and molecular ﬁndings, we performed molecular analysis on the FFPE tissues from both the conventional type and
FV components of the left lobe nodule via microdissection. Interestingly, the conventional PTC component harbored the novel
YWHAG-BRAF fusion (35.15% RNA reads) and EIF1AX mutation
[c.338–1G>C, altered allele frequency (AAF) 27.21%] concurrently,
while the FV component carried only the YWHAG-BRAF fusion
(31.9% RNA reads). A minute fraction of EIF1AX mutation (AAF
1.23%) found in the FV component was likely due to contamina-

Fig. 2. Molecular characterization of FNA sample from 1.2 cm left lobe nodule. NGS revealed an in-frame novel YWHAG-BRAF fusion with 5 partner (exons 1) of YWHAG and
3 (exons 11–18) of BRAF. CR2: conserved region 2; RBD: RAS-binding domain.
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Fig. 3. A-D: The focus of PTC in the left thyroid lobe exhibits two distinct morphologic patterns. The majority of the lesion (A and B) shows follicular architecture (C,
higher magniﬁcation of the blue inset in B), but an inner well demarcated (black dots
53 in A and B) nodular component contains classical papillary architecture (D, higher
magniﬁcation of the green inset in B).
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Table 1
Imaging and laboratory results of all biopsied nodules.
Nodule
Location Size

Ultrasound
characteristics

FNA Cytology

Left lobe
1.2 cm

Hypoechoic

Suspicious for
follicular
neoplasm
(Bethesda IV)

Left isthmus
1.6 cm

Hypoechoic

Suspicious for
follicular
neoplasm
(Bethesda IV)

Right lobe
2.2 cm

Heterogeneous
echogenicities
including
isoechoic,
hypoechoic,
and
very
hypoechoic

Suspicious for
follicular
neoplasm
(Bethesda IV)

Molecular pathology

Surgical pathology

Fusion

Mutations

Fusion name: YWHAG-BRAF
Fusion location: Exon–Exon boundary
Frame status: In-Frame
5 partner: End Exon 1 [YWHAG,
NM_012479, Breakpoint (RNA):
chr7:75,988,039]
3 partner: Start Exon 11 [BRAF,
NM_004333, Breakpoints (RNA):
chr7:140,481,493]

Gene: EIF1AX
Position: chrX:20,148,726
Nucleotide chg.: c.338–1G>C
(NM_001412.3)
AA chg.: A113 splice mutation
Altered allele freq.: 16.7%

PTC, mixed
conventional type and
follicular variant with
corresponding
molecular ﬁndings (see
Fig. 3)

Gene: KRAS
Position: chr12:25,380,276
Nucleotide chg.: c.182A>G
(NM_004985.4)
AA chg.: p.Q61R
Altered allele freq.: 10.5%
Gene: NRAS
Position: chr1:115,256,529
Nucleotide chg.: c.182A>G
(NM_002524.4)
AA chg.: p.Q61R
Altered allele freq.: 25.4%

PTC, follicular variant

PTC, follicular variant

Gene: TP53
Position: chr17:7,578,403
Nucleotide chg.: c.527G>A
(NM_000546.5)
AA chg.: p.C176Y
Altered allele freq.: 2.7%

tion during microdissection. Thus, the single left lobe nodule exhibited two distinctive histological variants of PTC, which harbored
two different pathogenic gene alterations (i.e., YWHAG-BRAF fusion
with and without EIF1AX mutation).
During the patient’s six months post-operative visit, repeat ultrasound showed overall stable nodules in the right lobe including a 2.2 cm upper pole solid hypoechoic nodule. However, given
the multifocality of disease in the contralateral thyroid, FNA was
recommended for this nodule, which yielded a cytologic diagnosis of “SFN (Bethesda Category IV)”. Molecular pathology revealed
two pathogenic mutations, in NRAS and TP53 (Table 1). After a second discussion regarding multifocal thyroid cancer on the left and
the risk of malignancy in the right lobe nodule, the patient elected
for a completion right thyroidectomy. During that surgery, the surgeon noted a large ﬁrm nodule in the right superior pole as well
as smaller less ﬁrm nodules in the mid/lower pole without evidence of gross extrathyroidal extension, and there was no evidence
of lymphadenopathy in the right central neck. Histopathologic examination of the completion thyroidectomy specimen revealed two
organ-conﬁned foci of FVPTC. The patient has healed well from
surgery with no complications, has had euthyroid labs on 125mcg
of levothyroxine daily, and will be followed with thyroglobulin levels.

activate the MAPK pathway by relieving autoinhibition through the
loss of autoinhibitory N-terminal conserved region 1 (CR1) domain
of B-Raf [14], and plays an important role in tumorigenesis [15].
More importantly, BRAF V600E mutation or fusions are not found
in benign thyroid nodules. To date, at least 20 out of 62 BRAF
fusion partner genes (LMO7, AKAP9, SND1, AGK, AP3B1, BCL2L11,
FAM11442, MKRN1, MACF1, ZC3HAV1, CCNY, ERC1, SVOPL, OSBPL9,
PRKAR2B, SCRIB, KIAA1549, PARP12, CUL1, OPTN) have been identiﬁed in thyroid carcinoma [6,16]. Occasionally, BRAF fusion and
V600E mutation can be found concurrently in the same lesion [15].
In one study, 11 partner genes involved in BRAF fusions were identiﬁed in 13 (2.7%) of 484 PTC cases [17]. The majority (8/13) of the
BRAF fusion related PTCs show the morphological features of classic variant or tall cell variant PTC, referred to as BRAF V600E-like
phenotype [7,17]. These features are correlated with a signiﬁcantly
poor prognosis [12,13,18–20]. In our case, YWHAG-BRAF fusion was
found in a nodule showing both classical PTC areas (which also
harbored an EIF1AX mutation) and FVPTC areas (which harbored
only the BRAF fusion). This is an interesting and unexpected ﬁnding, given that BRAF fusions typically occur in classical PTC, while
EIF1AX mutations tend to be associated with follicular-patterned
thyroid tumors.
As a discovery, the exact function of the YWHAG-BRAF fusion
in tumorigenesis remains unclear. Previous research shows that
the BRAF signaling pathway can be activated by losing the autoinhibitory N-terminal CR1 domain, a common consequence in BRAF
fusions, including the current YWHAG-BRAF fusion. This mechanism
of loss of autoinhibition is different from that of the direct activation of the CR3 kinase domain through phosphorylation induced
by BRAF V600E mutation [14]. Studies show that altered BRAF can
be activated either as a monomer or a dimer [21]. Naturally, 14–
3–3 proteins can activate BRAF function by direct binding through
bridging at the pS729 site of BRAF protein (retained in our fusion
protein) and resulting in dimerization [22,23]. More interestingly,
14–3–3 gamma isoforms are almost dimeric through the interac-

Discussion
Mutation and rearrangement of the BRAF gene play signiﬁcant
roles in tumorigenesis in various cancers, including thyroid cancer, melanoma, gliomas, and lung cancer [6]. The activation of BRaf transduces the signal to the downstream factors and activates
the entire Mitogen Activated Protein Kinase (MAPK) pathway. BRAF
V600E mutation is the most common (35% to 70%) pathogenic mutation found in PTC [7–11]. More than 60% of the conventional type
of PTC is driven by genetic aberrations involving the BRAF gene
[9,12,13]. Besides point mutations, BRAF fusion can constitutively
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tion domain, which is partially encoded by exon1 of YWHAG (retained in our YWHAG-BRAF fusion product) [24]. Thus, BRAF activation can be regulated through two possibilities by the novel
YWHAG-BRAF fusion: 1. facilitated dimerization by 14–3–3 gamma
encoded by YWHAG; 2. bridging by 14–3–3 gamma. Of note, the
breakpoint at exon 11 of the BRAF gene in YWHAG-BRAF fusion is
a recurrent site, found in other tumors [16,21,25,26]. The further
study of BRAF fusion and disease prognosis in thyroid carcinoma is
warranted.
Another critical gene found in thyroid cancer tumorigenesis is
EIF1AX, which encodes one of the essential factors involved in the
initiation of eukaryotic translation. According to one study, EIF1AX
mutations are found in 4.2% of thyroid nodules including benign
nodules, well-differentiated thyroid carcinomas, poorly differentiated, and anaplastic thyroid cancers [4]. The most common EIF1AX
mutations occur in two hotspots: the mutation cluster in exon 2
and the codon A113 splice mutation, which affects the splice sites
of c.338–1 G on exon 6 [4,27]. One of these two hotspots, i.e., the
codon A113 splice mutation, is identiﬁed in our case. The previous data suggest that A113 splice mutation located at exon 6 of
EIF1AX is associated with higher grade and aggressive progression
in thyroid cancer [4,17,27,28]. Recent research from our institute
reported a 4.5% incidence of EIF1AX mutation in 904 FNA nodules, with 50% mutations occurring at the splice site of c.338–
1 G or c.338–2A. Among these nodules, the most common diagnoses are follicular thyroid carcinoma (27%) and follicular variant
of papillary thyroid carcinoma (FVPTC, 27%). Notably, the pathological diagnosis correlates with the presence or absence of coexisting
mutations with EIF1AX. Overall, an isolated EIF1AX mutation conferred a 36.4% risk of malignancy (ROM), while the ROM was signiﬁcantly higher in nodules with concurrent RAS, TERT, TP53 mutations (from 71.4% to 100%) [29], which is consistent with other
studies [17,28].
It was previously thought that BRAF alteration is mutually exclusive with aberrations in EIF1AX in thyroid cancer, suggesting
their distinctive roles in tumorigenesis. However, in our case, the
novel YWHAG-BRAF fusion and EIF1AX mutation are found concurrently in the same lesion. The component with conventional
PTC morphology harbors YWHAG-BRAF fusion and EIF1AX mutation
concurrently, while the follicular variant component carries only
the YWHAG-BRAF fusion. As suggested by a previous study, the conventional type of PTC is associated with higher-risk disease and
signiﬁcantly poorer long-term outcomes, including increased risk
for disease recurrence and cancer-speciﬁc death than the follicular variant of PTC [30]. Our results suggest that the conventional
PTC harboring YWHAG-BRAF fusion with concurrent EIF1AX mutation might present a potentially more aggressive malignancy than
the FVPTC harboring YWHAG-BRAF fusion only.
Recently, the highly selective MAP pathway kinases inhibitors,
such as Sorafenib and Vemurafenib, have shown signiﬁcant efﬁcacy for treating tumors harboring BRAF mutations [21,31]. Increased testing of thyroid cancers, particularly the clinically aggressive forms, for BRAF mutation or rearrangement will facilitate targeted therapy as a more effective and personalized
treatment.
In conclusion, we identiﬁed a novel YWHAG-BRAF fusion with a
concurrent EIF1AX mutation in a single nodule of PTC with coexisting conventional and follicular variant histology. The results further
contribute to understanding the tumorigenesis of thyroid cancer
and the insight into the evolution of the tumor driven by different
mechanisms, which could eventually improve clinical outcomes by
targeted therapy.
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